In this OncLive News Network program, Julio C. Chavez, MD, of Mayo Clinic in Jacksonville, Florida, and Tycel Phillips, MD, of City of Hope in Duarte, California, discuss the evolving treatment landscape for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in the third-line setting and beyond. The physicians review available options and unmet needs, particularly for patients with CAR T-refractory disease, before focusing on the bispecific antibodies epcoritamab and glofitamab. They examine pivotal efficacy and safety data, the differences between continuous and fixed-duration treatment, and subcutaneous versus intravenous administration. They also share practical strategies for managing cytokine release syndrome in the outpatient setting, preventing infections, and monitoring immune recovery. The discussion then turns to patient selection, emerging bispecific-based combinations, and potential use in earlier lines of therapy. They close with key takeaways for community oncologists integrating bispecific antibodies into practice.
Julio C. Chavez, MD, of Mayo Clinic in Jacksonville, Florida, and Tycel Phillips, MD, of City of Hope in Duarte, California, open their discussion by outlining the treatment landscape for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in the third-line setting.
Dr. Phillips reviews the pivotal EPCORE NHL-1 trial of subcutaneous epcoritamab in heavily pretreated relapsed/refractory large B-cell lymphoma, including patients with prior CAR T-cell therapy and double-hit disease.
